You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 15, 2022

Thailand’s New Legal Framework for Kratom

Subscribe to Updates

In 2021, Thailand passed the updated Narcotics Act (No. 8) B.E. 2564 (2021), which removed kratom (Mitragyna speciosa) from the list of prohibited substances, eliminated kratom-related offenses on the basis that its consumption is part of traditional Thai cultural norms, and allowed possession and consumption.

On August 26, 2022, Thailand published the Kratom Plant Act B.E. 2565 (2022) in the Government Gazette, and the law came into effect the following day. With the aim of encouraging economic activity related to kratom, the act regulates the trade, sale, consumption, study, and advertising of kratom leaves (alone or as an ingredient in food) in Thailand.

Importing and Exporting Kratom Leaves

Importing and exporting kratom leaves without obtaining a license from the secretary-general of the Narcotics Control Board (NCB) is prohibited under the Kratom Plant Act. Eligible license recipients include:

  • Thai nationals over twenty years old and residing in Thailand;
  • Juristic persons registered under Thai law;
  • Community enterprises under the law; and
  • Government agencies.

A license is valid for five years, and importers and exporters must still notify the NCB when importing or exporting kratom leaves. An exception to the licensing requirement is bringing kratom leaves in and out of Thailand for personal consumption, therapy, and treatment of an illness. The amounts allowed for international travel are to be specified in ministerial regulations. If the amount of the kratom leaves exceeds this allowance, the transport will be considered importing or exporting of kratom leaves, triggering the licensing requirements described above.

Violation of these requirements is subject to imprisonment for up to one year, a maximum fine of THB 100,000, or both.

Selling Kratom

The Kratom Plant Act also allows the sale of kratom leaves alone or as an ingredient in food, subject to certain conditions. Under the law, sales of kratom include selling, dispensing, distributing, exchanging, or giving the substance to others. The laws measures pertaining to this are intended to protect people from the potential harm of consuming or misusing kratom.

It is prohibited to sell kratom leaves or food that contains kratom leaves as an ingredient to persons under 18 years old, and pregnant or breastfeeding women. The law also authorizes ministers of the Ministry of Justice and the Ministry of Public Health to prohibit selling kratom to additional persons. Sellers must post an announcement at their place of sale (including electronic points of sale) noting the prohibition on selling kratom to these parties. Violating one of these prohibitions or not posting the required announcement or notice is punishable by a fine of up to THB 30,000.

There are two exceptions. Selling to the restricted persons mentioned above may be allowed only if done for medical or educational purposes, defined specifically as follows:

  • Treatment of disease, therapy, or relief of illness under the supervision of a medical practitioner, dental practitioner, Thai traditional medicine practitioner, or traditional medical professional under the law related to the Thai traditional medical profession; or
  • Study, analysis, or research carried out by a government agency that is responsible for conducting medical, pharmaceutical, or scientific research or education, or providing medical, pharmaceutical, or scientific services for the benefit of medical or pharmaceutical, Thai Red Cross Society, or educational institutions.

Besides the prohibitions on selling to certain parties, some locations and points of sale are also off limits for selling kratom leaves or food containing kratom leaves. Kratom leaves by themselves may not be sold in educational institutions, dormitories, parks, zoos, amusement parks, vending machines, or other places specified in announcements by ministers of the Ministry of Justice and the Ministry of Public Health. Violations are subject to a fine of up to THB 50,000—and up to twice that (i.e., THB 100,000) if the sale is to one of the prohibited parties mentioned above.

While consumption of kratom is now legal following its removal from the narcotics list, it is prohibited to consume kratom leaves mixed with narcotic drugs, psychotropic substances, dangerous substances, or any other substance specified by the Ministry of Justice, except when done for the specific medical or education purposes given above. Violation is subject to a maximum fine of THB 50,000.

Advertising

Advertising or promoting the consumption of kratom leaves mixed with narcotics or psychotropic substances, drugs and dangerous substances, or other designated substances is also prohibited under the Kratom Plant Act. This is a comprehensive ban on inducing people to consume any of these kratom-containing mixtures, covering advertisement or any type of marketing communication by means of public relations, news, publishing promotion, point-of-sale displays, direct marketing, sales, and online or computer advertising. Violations of this ban are subject to imprisonment for up to two years, a maximum fine of THB 200,000, or both.

Similarly, convincing others (including “encouraging, deceiving, intimidating, improperly influencing, or forcing”) to consume kratom leaves mixed with narcotic drugs, psychotropic substances, dangerous substances, or other designated substances is also prohibited. Violations of this prohibition are subject to imprisonment for up to one year, a maximum fine of THB 100,000, or both. Penalties can be doubled if the violation is committed against persons under age 18, pregnant or breastfeeding women, or any other person designated by the Ministry of Justice or the Ministry of Public Health, for a maximum sentence of imprisonment for two years and a fine of THB 200,000.

Conclusion

Overall, the Kratom Plant Act lays out a general framework that regulates importing and exporting kratom leaves and supervises the sale, consumption, advertising, and misuse of kratom leaves and food containing kratom leaves. However, there are still additional specific restrictions in various regulations or announcements from the NCB, Ministry of Justice, Ministry of Public Health, and other relevant agencies.

Furthermore, using kratom leaves in certain products can trigger other regulations. For example, using kratom leaves as raw materials or components of herbal products, drugs, and cosmetics may be subject to specific laws such as the Herbal Product Act, Drugs Act, or Cosmetics Act. The relevant provisions under the specific legislation will still apply—even though their restrictions and requirements could differ from those in the Kratom Plant Act.

Consequently, it is advised to seek local expert counsel before starting any business involving kratom, as it is still subject to numerous restrictions and requirements.

Related Professionals

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

July 13, 2026
Indonesia’s Halal Product Assurance Agency (BPJPH) has issued new regulations establishing clearer procedures for imposing administrative sanctions on businesses that violate halal product assurance requirements. BPJPH Regulation No. 2 of 2026 on the Imposition of Administrative Sanctions for Violations of Halal Product Assurance Implementation, issued on June 5, 2026, strengthens Indonesia’s halal compliance framework, as mandated under Law No. 33 of 2014 on Halal Product Assurance and Government Regulation No. 42 of 2024 on the Implementation of Halal Product Assurance. BPJPH Regulation No. 2/2026 also supports the upcoming mandatory halal compliance deadline of October 17, 2026, which will apply to a broad range of products and services, including imported food and beverages, slaughtering products and services, natural and quasi-drugs, health supplements, cosmetics, chemical and genetically engineered products, clothing and accessories, household goods, prayer equipment, stationery, and class A medical devices. Scope BPJPH is authorized to impose administrative sanctions for violations of halal product assurance requirements committed by businesses, halal inspection agencies (LPH), halal auditors, halal product process companion institutions (lembaga pendamping PPH), and halal product process companions (pendamping PPH). The head of BPJPH has authority to determine, cancel, or amend the imposition of administrative sanctions, including upon receipt of objections. This authority covers revocation of Halal Certificates (including foreign halal certificate registration numbers), withdrawal of goods from circulation, freezing of LPH operations, freezing of halal product process companion institutions, revocation of PPH companion institution registration numbers, revocation of halal auditor registration numbers, and revocation of LPH accreditation status. Administrative Sanctions Businesses may be subject to any of the following administrative sanctions: Written warning; Administrative fine; Revocation of the halal certificate, including revocation of foreign halal certificate registration numbers; and Withdrawal of goods from circulation. The regulation sets out the types of violations that may trigger these sanctions, with each
Read More
July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
Read More
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
Read More
June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
Read More